Abasic sites are among the most abundant DNA lesions and interfere with DNA replication and transcription, but the mechanism of their action on transcription remains unknown. Here we applied a combined structural and biochemical approach for a comprehensive investigation of how RNA polymerase II (Pol II) processes an abasic site, leading to slow bypass of lesion. Encounter of Pol II with an abasic site involves two consecutive slow steps: insertion of adenine opposite a noninstructive abasic site (the A-rule), followed by extension of the 3′-rAMP with the next cognate nucleotide. Further studies provided structural insights into the A-rule: ATP is slowly incorporated into RNA in the absence of template guidance. Our structure revealed that ATP is bound to the Pol II active site, whereas the abasic site is located at an intermediate state above the Bridge Helix, a conserved structural motif that is cirtical for Pol II activity. The next extension step occurs in a templatedependent manner where a cognate substrate is incorporated, despite at a much slower rate compared with nondamaged template. During the extension step, neither the cognate substrate nor the template base is located at the canonical position, providing a structural explanation as to why this step is as slow as the insertion step. Taken together, our studies provide a comprehensive understanding of Pol II stalling and bypass of the abasic site in the DNA template.
D
NA is under constant threat of damage by both endogenous and exogenous agents. Abasic (AP) sites represent the most abundant DNA damage observed under physiological conditions, with ∼10,000 formed in a human cell per day (1, 2) . These AP sites arise from spontaneous depurination as well as intermediates during base excision repair of oxidized and alkylated bases (3) . AP sites are potentially mutagenic as the base information is lost (Fig.  1A) . Although AP sites can be efficiently dealt with through the base excision repair and the nucleotide excision repair (NER) pathways, undetected lesions pose a challenge for fidelity of DNA and RNA synthesis and genome integrity (4) .
During DNA synthesis, AP sites are strong blocks for the replicative DNA polymerases (Pols) (4, 5) . Blocked DNA synthesis can be rescued by the action of translesion DNA synthesis (TLS). During TLS, high-fidelity replicative DNA Pols are switched transiently to TLS DNA Pols involving error-free or error-prone pathways. The nucleotide selectivity opposite AP site is dependent on the DNA template sequence and the Pol used (3, (6) (7) (8) . Interestingly, for the majority of replicative and repair DNA Pols, in vitro and in vivo studies have shown that A is predominantly inserted opposite the noninstructional lesion followed by G and T. This strong preference for adenine incorporation by replicative DNA Pols is termed the A-rule (9) (10) (11) . The superior base-stacking ability of adenine was proposed to be the driving force for preferential purine selection when incorporating a nucleotide opposite AP site (12) . Recently, a model of "amino acid side chain templating," revealed from studies of KlenTaq Fragment DNA Pol, provided significant mechanistic insights into the A-rule (13, 14) .
Several TLS DNA Pols from the X and Y family employ different, sequence-dependent mechanisms that might compete with the A-rule during AP site bypass (8, 15, 16) .
Similar to its effect on DNA replication, the presence of an AP site in DNA template results in Pol II transcriptional stalling at the lesion followed by slow subsequent transcriptional bypass, whose efficiency depends on the sequence context (17, 18) . While the structural analyses of replicative DNA Pols in complex with APcontaining DNA provided significant mechanistic insights into stalling and translesion bypass of the AP site by DNA Pols, the molecular mechanism by which Pol II stalls and bypasses AP sites is still unclear. Here we took a combined structural and biochemical approach to systematically investigate the impact of AP site on transcription in a step-wise manner. Our biochemical data showed that the presence of AP site strongly interferes with the insertion step-that is, the nucleotide incorporation opposite the AP sitewith AMP being preferentially inserted. The subsequent step in AP site bypass-that is, the next nucleotide extension step-is also significantly compromised. We also reported five crystal structures, which provide structural snapshots of the translesion bypass process of AP site by Pol II. Taken together, this study elucidates the molecular mechanism of transcriptional stalling and bypass of AP DNA lesion by Pol II.
Significance
Abasic DNA lesions are one of the most abundant types of DNA lesions and are frequent byproducts of normal cellular metabolism, and they represent intermediates in the base excision repair pathway. These DNA lesions can lead to DNA mutations and transcription errors and block replication and transcription. The molecular basis for RNA polymerase II (Pol II) stalling and bypass of abasic lesion remains elusive due to a lack of atomic structural information. Here we reported the structural snapshots of Pol II stalling and bypass of abasic DNA lesion in a step-wise manner and elucidated how bypass of the lesion leads to the errors in RNA transcripts. These results provide important mechanistic insight into understanding the biological consequences of these abundant mutagenic DNA lesions. 
Results
Pol II Stalled at an AP Site with a Slow and Preferential AMP Insertion.
To investigate the effect of AP site on Pol II transcription elongation, we performed in vitro transcription assays with purified yeast or mammalian Pol II using either a miniscaffold or fullbubble scaffold containing one AP site in a template DNA strand (Fig. 1B and Fig. S1 A and B) . With both scaffolds, we identified two consecutive steps in negotiation of Pol II with the lesion. Both yeast and mammalian Pol II showed very similar transcription patterns during transcription through the AP site. Both Pols stalled before the nucleotide incorporation opposite the AP site (insertion step) and immediately after incorporation (extension step). We also found that Pol II was able to slowly bypass the AP site and a substantial accumulation of the run-off product was observed with prolonged incubation with 1 mM NTP mixture (Fig.  1B and Fig. S1 A and B) , which was in agreement with previous studies (18, 19) . It is noticeable that the 9-mer product (or +1 product) was smeared, indicating different NTPs can be incorporated opposite the AP site (Fig. 1B and Fig. S1 A and B) and suggesting different nucleotides can be incorporated at this position (as short RNAs with a single nucleotide difference typically have different mobilities in PAGE-urea gels) (19) . We further tested the effect of AP site on nucleotide selectivity and found that Pol II obeys the A-rule of nucleotide addition against the AP site, with incorporation preference A > G >> U > C (Fig. 1B and Fig. S1 A and B) . Further biochemical analysis revealed that AMP incorporation was 10.7-fold more favored than GMP incorporation. This minor difference is in sharp contrast to the 2.8 × 10
5
-fold discrimination between incorporation of cognate AMP over GMP opposite the dT base on the nondamaged template in the NTP competition assay (Fig. S1 C and D) (20) . Taken together, these data indicate that Pol II adopts the A-rule to bypass the AP lesion slowly.
The conserved Pol II motif trigger loop (TL), which comprises two α-helices connected by a short flexible loop, plays critical roles in Pol II catalysis, transcription fidelity, pausing, and translocation (20) (21) (22) (23) . To understand whether TL affects AMP incorporation opposite the AP site, we employed a Pol II mutant with TL deletion (ΔTL) (Fig. 1C , ΔTL Pol II). We compared the incorporation rates of single AMP addition opposite the AP site or the nondamaged thymidine by WT and ΔTL Pol II, respectively ( Fig. 1C and Table S2 ). We found that while deletion of TL led to a 340-fold decrease in k pol for the nondamaged template, it only caused a sevenfold decrease in k pol for the AP-containing template, suggesting that ATP incorporation opposite the AP site is largely TL-independent. In addition, TL deletion only caused a mild decrease in NTP binding affinity (K D ): fivefold for nondamaged template and only 1.6-fold for the AP-containing template.
Structural Basis of AMP Addition Opposite the AP Site. To reveal the structural basis of how the AP site is accommodated at the Pol II active site, we first determined the crystal structure of the Pol II elongation complex (EC) containing an AP site at the i + 1 position (EC-I, Table S1 ). We found that the overall Pol II EC is in a posttranslocation state (Fig. S1E) . However, the AP site at the i + 1 register is located at an intermediate state that is half-way across the Bridge Helix of Rpb1, whereas an unmodified dT template is fully loaded to the i + 1 site and juxtaposed for base pairing with an incoming NTP ( Fig. 2A , PDB ID code 4BY1) (24) . The phosphate group of the AP site migrates ∼5 Å to form strong hydrogen bonds with R337 of Rpb1, and the base of DNA nucleotide at the i + 2 site interacts with the side chain of Y836 of Rpb1 by π-π stacking ( Fig. 2A) . Intriguingly, the R337-phosphodisester backbone interaction was also observed in Pol II stalled by a CPD dimer UV lesion at a similar intermediate location above the Bridge Helix (see more details in Discussion) (19, 25) . In addition, the intrinsic flexibility of the AP site might also induce different downstream template DNA conformations. Hence, the density could not be traced in this crystal structure in comparison with Pol II EC containing an unmodified template.
To further understand how an AP site affects nucleotide binding and incorporation, we solved the crystal structure of Pol II EC containing a nonhydrolysable ATP analog (AMPCPP) bound opposite the AP site (EC-II, Fig. 2B and Table S1 ). The AP site adopted a similar intermediate conformation across the Bridge Helix as was observed in the EC-I structure. AMPCPP was built in to fit the electron density in the Pol II active site ( Fig. 2 B and C) . We found that AMPCPP is held in the NTP addition site (A-site) despite lacking a Watson-Crick base pair with the AP site ( Fig. 2 B and C). In comparison with its unmodified counterpart, the ATP:dT pair (PDB ID code 4BY1), we found the base group of ATP is migrated ∼2 Å toward the AP site, which forms base stacking with the base pair of the i − 1 site and a stronger interaction with the side chain of T831 of Rpb1 on the Bridge Helix (Fig. 2C, Lower) . The phosphate group of AMPCPP also forms strong hydrogen bond networks with Pol II residues (Fig. 2C , Upper). Interestingly, the α phosphate group of AMPCPP moves away from the Metal A (Mg 2+ ion) and interacts with one water molecule chelated by E529 and Y769 of Rpb2. We found that the TL is in an open state (disordered), which is consistent with biochemical results. Taken together, while the ATP substrate is still bound in the A-site (presumably due to base stacking with the 3′ RNA end in the i − 1 site), the absence of nucleobase moiety of the AP site leads to a positional shift of the substrate and, in turn, causes the failure of a full assembly of the Pol II active site that is required for effective nucleotide addition. Unlike KlenTaq fragment DNA Pol (13) , no amino acid residue of Pol II is identified to form direct hydrogen bonds with the base of incoming ATP (from minor groove) opposite of the AP site to direct nucleotide selection of AMP over other nucleotides. The nucleotide selection pattern of Pol II is much more similar to the scenario of DNA Pol RB69 (26) , in which the incoming ATP is mainly stabilized by base stacking with the i − 1 base pairs. Intrinsic properties of purines with a superior base-stacking ability over pyrimidines may be a driving force for Pol II to select ATP or GTP opposite an AP site. However, we cannot rule out that TL residues (disordered in our structure) could transiently form hydrogen bonds with ATP, which may be attributed to the modest preference of ATP over GTP preference (∼10-fold).
The AP Site Substantially Slows Down the 3′ AMP Extension with the Next Cognate Substrate. To understand the molecular basis for AP site bypass by Pol II, we investigated the effect of the AP site on the step subsequent to the 3′ AMP incorporation (the extension step). In this experiment, we utilized a 9-nt RNA primer carrying 3′ AMP opposite the AP site and measured the rate of the RNA extension with individual NTPs (Fig. 3A) . The presence of an AP site substantially slows down nucleotide extension. We found that the incorporation of a cognate substrate (UTP for 5′ dA template) is the most effective, followed by ATP (Fig. 3A) . To quantitatively compare the impact of the AP site on the extension step versus the precedent insertion step, we carried out single nucleotide addition assays. We found that k obs of UTP incorporation at the extension step for the AP-containing template is 0.27 ± 0.02 min −1 , which is about twofold that of k obs of ATP incorporation opposite an AP at the insertion step (k obs = 0.15 ± 0.01 min −1 ). Taken together, the nucleotide incorporation efficiencies across the AP site at both steps dramatically decreased by ∼2,000-4,000-fold compared to the nondamaged template (Fig. 3B, Fig. S2 , and Table S2 ) (27) .
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Structural Insights into the Slow Extension
Step at 5′ of the AP Site.
To understand why nucleotide incorporation at 5′ of the AP site is almost as slow as the previous AMP insertion step, we solved the crystal structure of Pol II EC (scaffold in Fig. 3A ) to mimic the state poised for the next nucleotide incorporation (extension) (EC-III, Table S1 ). The overall Pol II EC adopted a posttranslocation state register with the AP site already translocated to the i − 1 position (Fig. 3D) . While the AP site at the i − 1 position could be perfectly built into density, the downstream template nucleotide dA at the i + 1 position had very poor density (Fig. 3E) . The lost base stacking between the AP site and the next 5′ nucleotide in the template could be responsible for the flexibility of dA at the i + 1 position. We also observed an intriguing feature from the RNA primer when we modeled the 3′ RNA terminus into the canonical i − 1 position for RNA primer, where we found additional density that partially overlaps with the A-site (Fig. 3D and Fig. S4A ). This additional density is unique to EC-III, as we did not observe similar density in other structures like EC-I and EC-II. We speculate that this additional density could be attributed to a portion of Pol II EC with a frayed 3′ RNA due to a lack of base pair hydrogen bonding with its template (AP site) (structural details discussed in Fig. S4A ). Given the flexibility from both the RNA 3′ terminus and downstream dA template next to the AP site observed in the EC-III structure, one prediction is that this EC-III complex would be prone to backtracking in the absence of NTP. Indeed, as shown in Fig. 3C and Fig. S3 , when we incubated Pol II EC-III with TFIIS, a transcription factor that stimulates the transcript cleavage activity of Pol II for the 3′ RNA in the backtracked complex, we observed a substantial amount of cleavage products from the AP-containing Pol II EC, whereas no obvious cleavage product was observed for Pol II EC containing a nondamaged template. To find out how the AP site at the i − 1 template position affects UTP binding, we solved the structure of EC-IV by soaking crystals of EC-III carrying 3′A in the RNA opposite the AP site with 3.5 mM nonhydrolysable UTP analog (UMPNPP) (Table S1 ). Intriguingly, despite the fact that UMPNPP could form a Watson-Crick base pair with dA template at the i + 1 site, UMPNPP is accommodated in the entry site (E-site, a binding site previously identified for mismatched substrate) (21, 28) instead of the canonical A-site at the Pol II active center (Fig. 3F and Fig. S4 B and C) . The downstream dA template is flexible, with less defined electron density (Fig. 3F) . The flexibility of dA at the i + 1 register may reduce the possibility to establish a stable Watson-Crick base pair with incoming UTP. Another potential reason is that transient flipping out of 3′ RNA overlapping with the A-site could also disturb the UTP incorporation. In conclusion, this structural feature is consistent with our biochemical data that UTP incorporation at the extension step is substantially slow.
To investigate whether the AP site affects transcription elongation at the step subsequent to UMP incorporation 5′ of the AP site, we performed in vitro transcription assay using the RNA primer carrying the 3′ UMP to base pair with 5′ dA of the AP site to mimic the state after UTP is incorporated opposite the 5′ dA template. As shown in Fig. 4A , we found that the template-dependent cognate GMP incorporation for the APcontaining template occurred at a rate similar to the nondamaged template. The rate of GMP incorporation for the APcontaining template (k obs ) was lowered by ∼fourfold compared with the unmodified template at a lower GTP concentration (25 μM) (Fig. 4B) . Hence, AP site has little effect on transcription elongation after insertion and extension steps. Here we elucidated the molecular mechanism of Pol II stalling on the AP site and transcription bypass in a step-wise manner (Fig. 5) . We found two consecutive AP-induced Pol II transcriptional stallings that correspond to slow insertion and extension steps. To understand the structural basis of the first Pol II stalling state, we solved the structures of EC-I (without NTP) and EC-II (with bound NTP), representing the states when Pol II first encounters an AP site (register n). In the first stalled state, we found that the upstream RNA/DNA hybrid is in a canonical posttranslocation register, but the AP site is located above the Bridge Helix as an intermediate state not fully loaded to the active site. Since the AP site lacks a nucleobase group, it cannot support effective template-dependent NTP insertion. As a result, both rates (k pol ) and selectivity of NTP incorporation significantly decreased. We observed that AMP (followed by GMP) is preferentially incorporated (A-rule) by Pol II. To further understand the structural basis of the A-rule, we solved EC-II with AMPCPP bound opposite the AP site. Interestingly, we found that AMPCPP binds to the addition site opposite the AP lesion, suggesting that base stacking with the i − 1 base pair is likely the driving force for ATP binding. The TL is in an open and disordered conformation, which is consistent with slow nucleotide addition. To understand the second stalling, we further solved the structure of EC-III, mimicking the state after AMP is incorporated opposite the AP lesion. In this structure, we found that while the overall Pol II EC moved to the next posttranslocation state register (n + 1), a significant flexibility for both AMP at the 3′ RNA terminus as well as the 5′ template nucleotide adjacent to the AP lesion was observed due to a lack of base-stacking interactions and base pair restraint for the AMP:AP pair. As a result, the position of incoming NTP is also compromised, as shown in EC-IV structure. We found that the cognate UTP fails to reach the A-site and largely remains at the E-site. The E-site is located at the entrance to the secondary pore in Pol II, and it harbors noncomplementary NTP bound to the active center. Moreover, the instability of the DNA/RNA scaffold with AMP against the AP site promotes Pol II backtracking. We speculate that, occasionally, when the template base (dA) moves into the canonical i + 1 template position, UTP can rotate into the A-site and form the Watson-Crick base pair and proceed with the template-dependent addition, whereas ATP would be rejected due to a mismatched base pair. These structures offer structural insight into understanding why the extension step is also very slow and does not obey the Arule. Once UTP is incorporated into RNA and Pol II moves forward to the i + 2 site, the AP lesion would be sandwiched by the nondamaged Watson-Crick base pair. Hence, the impact of the AP site on downstream nucleotide binding and incorporation would be minimal, as revealed by our biochemical data in the absence and presence of TFIIS (details in Fig. S5 ). Downstream Pol II elongation after the extension step is similar to the transcription on the nondamaged template.
Some Y family DNA Pols, such as Sulfolobus solfataricus Dpo4, generate predominantly −1 frameshift mutations when they bypass the AP lesion in error-prone mode (29, 30) . It is also termed the "5′ rule," in which Dpo4 loops out the AP lesion and uses the 5′ base adjacent to the AP site to instruct nucleotide incorporation (8) . However, our structural data do not provide structural evidence to support this potential frame-shift mechanism during Pol II bypass of the AP site (as detailed in Fig. S6 ).
No Evidence to Support "Amino Acid Templating" A-Rule Mechanism
Employed by Pol II. It was reported that DNA Pol KlenTaq uses a tyrosine side chain of the O-helix to form a hydrogen bond with incoming ATP or GTP (mimicking base pairing) and direct preferential purine incorporation opposite an AP site, termed amino acid templating mechanism (13, 14) . To investigate whether Pol II has a similar template-independent mechanism, we examined the amino acid sequence of the BH domain (functionally equivalent to the O-helix) and identified a highly conserved tyrosine, Rpb1 Y836, as a potential donor forming an H bond with ATP bound opposite the AP site. However, further 3D structural analysis showed Y836 on all Pol II structures adopts one orientation, where the phenolic OH group is too far away to form direct hydrogen bonds with incoming ATP (Fig. S7) . In fact, Y836 is located at the downstream channel side of BH, which may function as the pedal for the nucleotide of template translocation crossing over BH (from the i + 2 to the i + 1 position) (31) . Although our current structural data suggest that the amino acid templating of the A-rule is unlikely a suitable mechanism for Pol II, this subject warrants further investigation, and we cannot rule out the possibility of amino acid templating via transient interactions from residues of the Pol II TL or the other domains in the active site.
Further Insights into Pol II Bypass of CPD and the AP Site. Many DNA lesions lead to transcription stalling and misincorporation during transcription by Pol II, termed transcriptional mutagenesis (TM) (32) (33) (34) . The lesion-induced transcription stalling triggers transcription-coupled repair (TCR). Alternatively, cellular tolerance to DNA lesions can be achieved by slow TLS without repair. The TLS allows synthesis of the full-length functional RNA for the gene and also eliminates a chance of collision of the lesion-arrested Pol II with replication machinery. Pol II has an intrinsic capacity for adopting either error-free or error-prone TLS of many lesions (19, 25, (35) (36) (37) (38) (39) . If the bulky lesion can be properly positioned in the active center for base pairing with the incoming NTP, Pol II will ensure error-free bypass (36-38). Otherwise, Pol II is likely to adopt error-prone routes and follow the A-rule (19, 25) . Indeed, there are many mechanistic similarities in the TLS of bulky cyclobutane pyrimidine dimer (CPD) lesion and nonbulky AP site by Pol II (Fig.  S8 ). In the structure of the intermediary state with the CPD in position i + 1/i + 2, the i + 1 base (3′ T) of CPD is positioned above the Bridge Helix, a similar intermediate position observed for the AP site in this study where the canonical i + 1 template site is unoccupied. Intriguingly, we found that the R337-template phosphodisester backbone interaction is also structurally conserved between Pol II stalled at an AP site and Pol II stalled by a CPD lesion (19, 25) , holding CPD or AP lesion above the Bridge Helix. This impaired loading of the damaged template in the active site appears to be a common structural feature that obeys the A-rule or purine rule because both ATP and GTP are highly preferred susbtrates for these DNA lesions. As a result, the NTP is bound and slowly incorporated in a template-independent manner. Purine nucleotides (ATP or GTP) are more favored because of their stronger base-stacking property in comparison with their pyrimidine counterparts (CTP or UTP). Another striking similarity between AP and CPD lesion bypass is that the next extension step is slow but template-dependent. Pol II catalyzes slow, templatedirected nucleotide incorporation opposite the 5′ moiety of these lesions after their translocation to the active site, which enables nonmutagenic bypass of lesions (19, 25, 38, 39) done by both yeast and mammalian Pols. This indicates an evolutionarily conserved mechanism to bypass one of the most abundant AP DNA lesions. The common mechanism for Pol II bypass of the CPD and AP sites may also apply for the other types of DNA lesions if they trap Pol II in the intermediate translocation state characterized in our present work.
Implications of AP Site-Induced Transcripiton-Coupled Repair. Our present study provides mechanistic insight into the enigmatic TCR of AP sites. While the AP sites are mainly repaired via base excision repair pathway, sevearal genetic studies suggest that they can be repaired by the NER pathway in the highly transcribed genes (18, (40) (41) (42) . The NER pathway removes bulky, helix-distorting lesions, such as bulky CPDs. There are two major subpathways of NER: global genomic NER (GG-NER) and transcription-coupled NER (TC-NER or TCR) (43) . These subpathways share the identical downstream DNA repair steps . The second stalled state (EC-III) is characterized by a significant structural flexibility for both 3′ AMP and the 5′ template nucleotide adjacent to the AP site. This is due to a lack of stacking interactions and base pair restraint, which interferes with binding of the incoming cognate UTP. As a result, UTP largely occupies the flipped-out conformation in the E-site (EC-IV). Once the slow extension step is completed, Pol II rapidly escapes from the lesion, with the rate similar to transcription on the nondamaged template (n + 2 to n + 3).
but have distinct initial lesion recognition steps. In GG-NER, a lesion-associated major distortion in the DNA helix is recognized directly by dedicated proteins such as XPC/HR23B or DDB complex, whereas in TCR, RNA polymerase stalling at a lesion triggers the inititation of TCR (43) . Intriguingly, it was reported that the AP sites in the transcribing strand in yeast are removed by TCR instead of GG-NER (40) . Given that AP sites are not bulky, helix-distorting lesions, it was not clear how they stall Pol II and whether the TCR of AP sites was different from the canonical TCR. Therefore, our data that Pol II is stalled by AP sites by inhibiting both insertion and extension steps may provide a sufficient time for initiation of TCR. Intriguingly, we found that the AP site and CPD lesion are positioned in a similar intermediate state above the Bridge Helix in the stalled Pol II (Fig. S8) . These structural and biochemical similarities between interaction of Pol II with nonbulky AP site and bulky CPD suggest that the initiation of TCR of both lesions occurs by the canonical TCR pathway (18, (40) (41) (42) (43) . The question of whether the similar mechanism is employed for TLS and TCR of the other types of nonbulky DNA lessions warrants further investigation.
Materials and Methods
Materials. Saccharomyces cerevisiae Pol II was purified as previously described (21, 44) . The template and nontemplate DNA oligonucleotides were purchased from IDT. AP sites in duplex DNA consist of an equilibrating mixture of the ring-closed acetal (99%) and the ring-opened aldehyde (1%) (45) . Due to the instability of natural AP sites, tetrahydrofuran was used as an AP site analog to study the influence of such lesions on Pol function (Fig.  1A) . DNA templates containing the AP site analog and RNA primers were purchased from TriLink Biotechnologies. RNA primers were radiolabeled using [γ-32 P] ATP (PerkinElmer) and T4 Polynucleotide Kinase (NEB). Ultrapure NTPs were purchased from Affymetrix.
In Vitro Transcription Assays with Miniscafflod. The assays were carried out as previously described (27, 46 Other steps are the same as above. Nonlinear-regression data fitting was performed using Prism 6. The time dependence of product formation was fit to a one-phase association equation to determine the observed rate (k obs ).
In Vitro Transcription Assays with Full-Bubble Scaffold. Pol II ECs were assembled on synthetic nucleic acid scaffolds as previously described (19) . Briefly, the 5′ radioactively labeled 9-nt RNA was annealed to the lesion-free or AP-containing template DNA oligonucleotide and then incubated with purified Pol II (yeast RPB1 WT, yeast Rpb1-TL deletion, or calf-thymus Pol II), followed by the subsequent addition of the nontemplate DNA oligonucleotide. Reactions were performed in transcription buffer (TB40): 20 mM Tris·HCl, pH 7.9, 5 mM MgCl 2 , 40 mM KCl, 10 μM ZnSO 4 , 3 mM 2-mercaptoethanol, and 20 μg/mL acetylated BSA. The resulting Pol II ECs were then diluted with 0.5 mL of TB40 and purified from the unincorporated ATP and nucleic acids using Amicon Ultra (Millipore) centrifugal filers with a 100-kDa molecular mass cutoff (47) .
In vitro transcription assays with lesion-free and AP-containing Pol II EC were performed as described (19, 48) . Briefly, Pol II EC complex was incubated at 24°C (yPol II) or 37°C (ctPol II) for various times with 1 mM NTPs or individual NTP in transcription buffer and stopped by addition of the gel-loading buffer (5 M urea, 25 mM EDTA, final concentrations). To facilitate detection of the full-length lesion bypass product (RO, 48-nt), the AP-containing Pol II ECs were also incubated with a mixture of NTP* containing a terminator chain NTP (1 mM ATP/GTP/UTP and 100 μM dCTP), which generated a shorter RNA product (RO*, 14-nt or +5 product) as described (19) . The 32 P-labeled RNA products were resolved in 20% polyacrylamide 7 M urea gels and were visualized using a Typhoon 8600 scanner (GE Healthcare). The quantitative analysis was performed with ImageQuant software, and the nonlinear regression analyses were done in OriginPro (OriginLab). The k pol and K D parameters in Table S2 were obtained from hyperbolic fits of the observed ATP incorporation rates (k obs ) plotted versus the substrate concentration. The maximum polymerization rate (k pol ) and the dissociation constant (K D ) were obtained from the resulting data by a nonlinear fit using the following equation: (20, 48) .
NTP Competition Assays. Lesion-free Pol II EC (1-2 nM) formed with WT Pol II was incubated simultaneously with both cognate ATP (20 nM) and noncognate substrate GTP at increasing concentrations (0.1, 0.2, 0.5, and 1 mM). On the other hand, AP-containing Pol II ECs were incubated with ATP (500 μM) and GTP at increasing concentrations (0.5, 2, 3, and 5 mM). The reactions were stopped with gel loading buffer after various incubation times (10 min for lesion-free template and 40 min for AP-containing DNA template). The products of AMP incorporation were discriminated from the products of GMP incorporation by their different mobilities on the gel. The fidelity parameter k pol /K D was calculated from the ratio of the correct (or preferential) to misincorporation RNA products accumulated in the same sample and its normalization to the [ATP]/[GTP] ratio (19) .
TFIIS-Stimulated Cleavage Assay. Recombinant TFIIS purification and cleavage reactions were previously described with slight modifications (46, 49) . Assembled Pol II ECs were mixed with different concentrations of NTPs without MgCl 2 . The reaction mixture was then incubated with an equal volume of solution containing TFIIS and MgCl 2 in elongation buffer. Final reaction conditions were 100 nM Pol II, 25 nM scaffold, 200 nM TFIIS, and 5 mM MgCl 2 . Reactions were quenched at various time points by the addition of one volume of 0.5 M EDTA (pH 8.0). Products were separated by denaturing PAGE as described above. The observed cleavage rates (k obs ) were determined with two-phase decay-fitting equations.
X-Ray Crystallography Setup and Analysis. The DNA/RNA scaffold was obtained by annealing template DNA, nontemplate DNA, and RNA oligonucleotides at a ratio of 1:2:2. The Pol II EC was assembled as previously described (21) . A concentration of 6-8 mg/mL complex (defined by Pol II concentration) was used to screen and optimize crystals. The Pol II EC crystals were grown using the hanging drop method in solutions containing 390 mM (NH 4 ) 2 HPO 4 / NaH 2 PO 4 (pH 6.0), 50 mM dioxane, 10 mM DTT, and 9-13% (wt/vol) PEG6000. Crystals were transferred to cryo buffer by three steps as previously described (21) . For Pol II EC with UMP or AMP analog, Pol II EC crystals were soaked with 3.5 mM UMPNPP or 5 mM AMPCPP (Jena Bioscience) and 5 mM MgCl 2 overnight in the cryo buffer.
Diffraction data were collected at beamlines 5.0.1 and 8.2.1 at the Advanced Light Source, Lawrence Berkeley National Laboratory, as well as beamline 9.2 at the Stanford Synchrotron Radiation Lightsource. The programs MOSFLM (50) and SCALA from the CCP4 program suite (51) were used to produce structure factor files, which were further analyzed by the UCLA Diffraction Anisotropy Server (52). Molecular replacement was carried out with PHENIX (53) using unmodified Pol II EC (PDB ID code 2E2H) as a search model. Model building with a specific DNA/RNA scaffold and structural refinement were performed with COOT (54) and PHENIX, respectively. The statistics of data collection and refinement are summarized in Table S1 . The quality of these final models was checked with MolProbity (55) . All of the structural figures were rendered in PyMOL (https:// pymol.org/2/).
